Market closed
Fortress Biotech/$FBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fortress Biotech
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Ticker
$FBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
186
Website
Fortress Biotech Metrics
BasicAdvanced
$43M
-
-$2.69
1.83
-
Price and volume
Market cap
$43M
Beta
1.83
52-week high
$2.89
52-week low
$1.36
Average daily volume
333K
Financial strength
Current ratio
1.266
Quick ratio
0.948
Long term debt to equity
-4,422.871
Total debt to equity
-4,620.438
Interest coverage (TTM)
-7.61%
Management effectiveness
Return on assets (TTM)
-41.30%
Return on equity (TTM)
424,052.63%
Valuation
Price to revenue (TTM)
0.53
Price to book
1.8
Price to tangible book (TTM)
-4.49
Price to free cash flow (TTM)
-0.308
Growth
Revenue change (TTM)
-31.76%
Earnings per share change (TTM)
-68.24%
3-year revenue growth (CAGR)
-5.71%
3-year earnings per share growth (CAGR)
-39.06%
What the Analysts think about Fortress Biotech
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Fortress Biotech stock.
Fortress Biotech Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Fortress Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Fortress Biotech News
AllArticlesVideos
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
GlobeNewsWire·1 week ago
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
GlobeNewsWire·1 week ago
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Fortress Biotech stock?
Fortress Biotech (FBIO) has a market cap of $43M as of April 08, 2025.
What is the P/E ratio for Fortress Biotech stock?
The price to earnings (P/E) ratio for Fortress Biotech (FBIO) stock is 0 as of April 08, 2025.
Does Fortress Biotech stock pay dividends?
No, Fortress Biotech (FBIO) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Fortress Biotech dividend payment date?
Fortress Biotech (FBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Fortress Biotech?
Fortress Biotech (FBIO) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.